PL3066126T3 - Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTK - Google Patents

Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTK

Info

Publication number
PL3066126T3
PL3066126T3 PL14796468T PL14796468T PL3066126T3 PL 3066126 T3 PL3066126 T3 PL 3066126T3 PL 14796468 T PL14796468 T PL 14796468T PL 14796468 T PL14796468 T PL 14796468T PL 3066126 T3 PL3066126 T3 PL 3066126T3
Authority
PL
Poland
Prior art keywords
antibody
combination therapy
btk inhibitor
btk
inhibitor
Prior art date
Application number
PL14796468T
Other languages
English (en)
Inventor
Christian Klein
Yoshizawa TOSHIO
Yasuhiro TOMOKO
Original Assignee
F. Hoffmann-La Roche Ag
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Ono Pharmaceutical Co., Ltd. filed Critical F. Hoffmann-La Roche Ag
Publication of PL3066126T3 publication Critical patent/PL3066126T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
PL14796468T 2013-11-07 2014-11-04 Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTK PL3066126T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13192006 2013-11-07
PCT/EP2014/073640 WO2015067586A2 (en) 2013-11-07 2014-11-04 Combination therapy of an anti cd20 antibody with a btk inhibitor
EP14796468.8A EP3066126B1 (en) 2013-11-07 2014-11-04 Combination therapy of an anti cd20 antibody with a btk inhibitor

Publications (1)

Publication Number Publication Date
PL3066126T3 true PL3066126T3 (pl) 2019-08-30

Family

ID=49552219

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14796468T PL3066126T3 (pl) 2013-11-07 2014-11-04 Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTK

Country Status (21)

Country Link
US (2) US20150125446A1 (pl)
EP (1) EP3066126B1 (pl)
JP (1) JP6478989B2 (pl)
KR (1) KR101874215B1 (pl)
CN (3) CN105792846A (pl)
AR (1) AR098328A1 (pl)
AU (1) AU2014345712B2 (pl)
BR (1) BR112016010271A2 (pl)
CA (1) CA2926893C (pl)
ES (1) ES2728350T3 (pl)
HK (1) HK1222803A1 (pl)
IL (1) IL244960B (pl)
MX (1) MX2016005801A (pl)
MY (1) MY178726A (pl)
NZ (1) NZ718792A (pl)
PH (1) PH12016500839A1 (pl)
PL (1) PL3066126T3 (pl)
RU (1) RU2727650C2 (pl)
TR (1) TR201907240T4 (pl)
TW (1) TWI524899B (pl)
WO (1) WO2015067586A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080513A1 (es) 2010-03-12 2012-04-11 Inmunogen Inc Moleculas de union cd37 y sus inmunoconjugados
WO2011152351A1 (ja) 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
RU2615999C2 (ru) 2011-11-29 2017-04-12 Оно Фармасьютикал Ко., Лтд. Гидрохлорид производного пуринона
ES2806506T3 (es) 2014-03-25 2021-02-17 Ono Pharmaceutical Co Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes
PL3262071T3 (pl) * 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Sposób stosowania immunokoniugatów anty-CD79b
EP3281943B1 (en) 2015-04-09 2023-06-28 ONO Pharmaceutical Co., Ltd. Process for producing purinone derivative
CA2986437A1 (en) 2015-06-08 2016-12-15 Debiopharm International, S.A. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
KR20180042423A (ko) 2015-08-28 2018-04-25 데비오팜 인터네셔날 에스 에이 Cd37 의 검출을 위한 항체 및 검정
US20190054090A1 (en) * 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
TWI747843B (zh) 2015-10-02 2021-12-01 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
CA3000746A1 (en) * 2015-10-02 2017-04-06 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
JP2020508436A (ja) 2016-12-07 2020-03-19 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3658584A1 (en) * 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
JP7418322B2 (ja) 2017-08-08 2024-01-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375931T3 (es) * 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
LT3284753T (lt) * 2002-10-17 2020-06-10 Genmab A/S Žmogaus monokloniniai antikūnai prieš cd20, skirti naudoti gydant išsėtinę sklerozę
ME00973B (me) * 2007-07-31 2012-06-20 Regeneron Pharma Humana antitjela prema humanom cd20 i postupak njihovog korišćenja
WO2011152351A1 (ja) * 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
EA032463B1 (ru) * 2011-10-19 2019-05-31 Фармасайкликс Элэлси Применение ингибиторов тирозинкиназы брутона (втк)
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
RU2615999C2 (ru) * 2011-11-29 2017-04-12 Оно Фармасьютикал Ко., Лтд. Гидрохлорид производного пуринона
EP2922827A4 (en) * 2012-11-20 2016-06-08 Celgene Avilomics Res Inc METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE

Also Published As

Publication number Publication date
MX2016005801A (es) 2016-11-29
PH12016500839A1 (en) 2016-06-13
CA2926893A1 (en) 2015-05-14
MY178726A (en) 2020-10-20
ES2728350T3 (es) 2019-10-23
AR098328A1 (es) 2016-05-26
IL244960B (en) 2021-08-31
US20200171153A1 (en) 2020-06-04
WO2015067586A2 (en) 2015-05-14
TWI524899B (zh) 2016-03-11
NZ718792A (en) 2020-05-29
IL244960A0 (en) 2016-05-31
TR201907240T4 (tr) 2019-06-21
CN105792846A (zh) 2016-07-20
CA2926893C (en) 2022-04-12
RU2016122232A3 (pl) 2018-06-18
AU2014345712A1 (en) 2016-05-05
EP3066126B1 (en) 2019-03-27
EP3066126A2 (en) 2016-09-14
AU2014345712B2 (en) 2019-10-17
WO2015067586A3 (en) 2015-07-30
KR20160079869A (ko) 2016-07-06
RU2727650C2 (ru) 2020-07-22
RU2016122232A (ru) 2017-12-08
US20150125446A1 (en) 2015-05-07
JP6478989B2 (ja) 2019-03-06
KR101874215B1 (ko) 2018-07-03
CN114632158A (zh) 2022-06-17
CN113995843A (zh) 2022-02-01
TW201521767A (zh) 2015-06-16
HK1222803A1 (zh) 2017-07-14
JP2016536298A (ja) 2016-11-24
BR112016010271A2 (pt) 2017-10-03

Similar Documents

Publication Publication Date Title
HK1222803A1 (zh) 抗體與 抑制劑的組合療法
HK1212240A1 (en) Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor ii cd20 bcl-2
HK1253022A1 (zh) Cd30×cd16抗體與pd-1拮抗劑的聯合藥物用於治療
EP2974377A4 (en) ELECTROMAGNETIC TRANSDUCER HAVING SPECIFIC INTERNAL GEOMETRY
EP2948458A4 (en) BTK INHIBITORS
IL245617A0 (en) Humanized antibody against kallikrein-2
EP2973430A4 (en) REPRESENTATION WITHOUT MESHING OF A GEOLOGICAL ENVIRONMENT
ZA201601895B (en) Combination therapy with an anti-ang2 antibody and a cd40 agonist
DK3778897T3 (da) Immunonkolytiske terapier
EP2984119A4 (en) RESIN FOR A TONER AND TONER
EP2984118A4 (en) RESIN FOR A TONER AND TONER
EP2948431A4 (en) BTK INHIBITORS
EP3083700A4 (en) Detection of an antibody against a pathogen
IL255353B (en) Combined treatment of anti-cd20 antibody with bcl-2 inhibitor and mdm2 inhibitor
CL2015001049A1 (es) Terapia de combinación de anticuerpos anti-her3
PT2981948T (pt) Inspeção de um elemento de segurança dotado de materiais magnéticos
GB201300706D0 (en) Antibody
GB201301864D0 (en) SQL visualizer
GB201303464D0 (en) Fast fused-multiply-add pipeline
HK1212477A1 (en) Magnetic centring device
DK3042099T3 (da) Sekundærfjeder med integreret tværanslag
GB2514823B (en) Anti-rattle device for a latch
DK3031310T3 (da) Elektromagnetisk afskærmet laminat
GB201321901D0 (en) A method of rational antibody design
AU2013900215A0 (en) A device for internal radiotherapy